Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 11,970,719 | 04/30/2024 | 2018-048 |
United States Of America | Published Application | 20240301376 | 09/12/2024 | 2018-048 |
The CRISPR-Cas system is now understood to confer bacteria
and archaea with acquired immunity against phage and viruses. CRISPR-Cas
systems consist of Cas proteins, which are involved in acquisition, targeting
and cleavage of foreign DNA or RNA, and a CRISPR array, which includes direct
repeats flanking short spacer sequences that guide Cas proteins to their
targets. Class 2 CRISPR-Cas systems are streamlined versions in which a
single Cas protein bound to RNA is responsible for binding to and cleavage of a
targeted sequence. The programmable nature of these minimal systems has
facilitated their use as a versatile technology that is revolutionizing the
field of genome manipulation, so there is a need in the art for additional
Class 2 CRISPR/Cas systems (e.g., Cas protein plus guide RNA combinations).
Researchers have shown that Class 2 CRISPR Cas protein and
their variants can be used in a complex for specific binding and cleavage of
DNA. The Class 2 CRISPR Cas complex utilizes a novel RNA and a guide RNA to
perform double stranded cleavage of DNA and the complex is expected to have a
wide variety of applications in genome editing and nucleic acid manipulation.
CRISPR, gene editing, genome, gene therapy, cell biology, Class 2